KEYNOTE-355: First-line pembrolizumab plus chemotherapy for metastatic triple-negative breast cancer

Share :
Published: 19 Sep 2021
Views: 1791
Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Prof Hope Rugo speaks to ecancer in an online interview for the virtual ESMO 2021 meeting about the final results from the KEYNOTE-355 study.

She explains that this was a randomised, double-blind phase 3 study of first-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for metastatic triple-negative breast cancer.

Prof Rugo goes into detail on the landscape of these types of treatment, the study design, the results and how those results can be interpreted. She reports that pembrolizumab combined with several chemo partners showed a statistically significant and clinically meaningful improvement in progression-free survival and was generally well tolerated. She concludes by discussing some of the questions the study raised.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.